Year: 2017
Type: article
Abstract: SBRT) regimens are able to overcome this and achieve high rates of local control [16][17][18][19].Additionally, exciting work is underway to investigate the immunomodulatory effects of SBRT in conjunction with immunotherapeutics in patients with oligometastatic disease [20].The development of new drugs and interventional devices has provided platforms to design new treatment algorithms for patients with oligometastasis.Whereas decades ago metastatic disease meant palliative care, new technical treatments may lead to longtime survival in selected patients.Advances in systemic therapy also extended the survival of patients with metastatic disease [21], rendering effective local therapy of increasing importance.Locoregional chemotherapy such as hepatic arterial infusion (HAI) plays a role in treating hepatic metastases from colorectal cancer in both the resectable and unresectable setting [22][23][24][25][26].For patients with unresectable metastases to the liver, HAI can be used with systemic chemotherapy to achieve increased response rates even in patients after progression on first-and second-line chemotherapy [27].Results show increased response and conversion to resection with the use of HAI and systemic therapy versus systemic therapy alone.The future is certainly better for patients with cancer, even with metastatic disease, and especially for patients with oligometastatic disease.
Source: Visceral Medicine
DOI: 10.1159/000458718
Authors: Nancy E. Kemeny, Beate Rau
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2590745513